U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11FN2O5
Molecular Weight 246.1924
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXIFLURIDINE

SMILES

C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=C(F)C(=O)NC2=O

InChI

InChIKey=ZWAOHEXOSAUJHY-ZIYNGMLESA-N
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1

HIDE SMILES / InChI
Molecular Formula C9H11FN2O5
Molecular Weight 246.1924
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Doxifluridine is a 5-fluorouracil prodrug that is being tested for the treatment of cancer. The cleavage into 5-fluorouracil occurs enzymatically via a nucleoside phosphorylase. Thus, doxifluridine is not active by itself and its antitumor activity is related to its metabolic conversion into 5-fluorouracil. Doxifluridine has neurotoxic adverse effects.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Thymidylate kinase
2
Target ID: P23919
Gene ID: 1841.0
Gene Symbol: DTYMK
Target Organism: Homo sapiens (Human)
Inhibitor
8297
Interacts
323
Interacts
323
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Withdrawn
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.
1985
Doxifluridine-induced neurotoxicity with normal dihydropyrimidine dehydrogenase activity.
2004 Jun 8
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
2006 Mar
Patents

Patents

JP2002541233A
400
JP2004523497A
81
JP2004534728A
78
JP2011525180A
180
JPH1192386A
1

Sample Use Guides

In Vivo Use Guide
460-600mg/m2/day per oral (Gastric cancer)
Route of Administration: Oral
In Vitro Use Guide
The cytotoxicity of Doxifluridine was determined in several cultured human tumor lines including tumors of the breast (47-DN, MCF-7), the colon (HCT-8), and the pancreas (Coto-357), as well as an osteosarcoma (MG-63) and a leukemia (HL-60). In vitro clonogenic assays were used to measure cytotoxicity following a 3hr drug exposure. Doxifluridine was less potent than was 5-fluorouracil or 5-fluoro-2'-deoxyuridine in all cells examined, exhibiting its best activity against the 47-DN [concentration that prevented 50% clonal growth compared to untreated control (LD50) = 32 uM] and MCF-7 (LD50= 35 uM) breast carcinomas and MG63 osteosarcoma (LD50 = 41 uM). Intermediate activity was observed against HCT-8 (LD50 = 200 uM)and Colo-357 (LD50 = 150 uM) gastrointestinal tumors. Doxifluridine had very poor activity against the HL-60 leukemia (LD50 = 470 uM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:53:07 GMT 2023
Edited
by admin
on Fri Dec 15 15:53:07 GMT 2023
Record UNII
V1JK16Y2JP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXIFLURIDINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
5'-DEOXY-5-FLUOROURIDINE
Systematic Name English
URIDINE, 5'-DEOXY-5-FLUORO-
Systematic Name English
NSC-758890
Code English
5-FLUORO-5'-DEOXYURIDINE
Systematic Name English
DOXIFLURIDINE [MART.]
Common Name English
RO 219738
Code English
Doxifluridine [WHO-DD]
Common Name English
CAPECITABINE RELATED COMPOUND B [USP-RS]
Common Name English
1-(.BETA.-D-5-DESOXYRIBOFURANOXYL)-5-FLUORURACIL
Common Name English
FURTULON
Brand Name English
FULTURON
Common Name English
doxifluridine [INN]
Common Name English
CAPECITABINE RELATED COMPOUND B [USP IMPURITY]
Common Name English
DOXIFLURIDINE [JAN]
Common Name English
DOXIFLURIDINE [MI]
Common Name English
FLUTRON
Common Name English
RO-219738
Code English
CAPECITABINE RELATED COMPOUND B
USP   USP-RS  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1557
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
Code System Code Type Description
DRUG BANK
DB12947
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
WIKIPEDIA
Doxifluridine
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
NSC
758890
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID2022967
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
EVMPD
SUB06389MIG
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
INN
4913
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
MESH
C025034
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
NCI_THESAURUS
C978
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
RS_ITEM_NUM
1090728
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
MERCK INDEX
m4755
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY Merck Index
CAS
3094-09-5
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
PUBCHEM
18343
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
ECHA (EC/EINECS)
221-440-1
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
FDA UNII
V1JK16Y2JP
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
ChEMBL
CHEMBL1130
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
CHEBI
31521
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
DRUG CENTRAL
958
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
SMS_ID
100000080814
Created by admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
PRIMARY
Related Record Type Details
Structure of CAPECITABINE
PARENT -> METABOLITE
Related Record Type Details
Structure of CAPECITABINE
PARENT -> IMPURITY
Related Record Type Details
Structure of DOXIFLURIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966